These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 11478135

  • 1. [Tumor markers in breast cancer].
    Harada Y, Ohuchi N, Ishida T, Ohnuki K.
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):1035-40. PubMed ID: 11478135
    [Abstract] [Full Text] [Related]

  • 2. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K, Karaki K, Watanabe K, Tsuda H, Konishi F.
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [Abstract] [Full Text] [Related]

  • 3. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer.
    Nakata B, Takashima T, Ogawa Y, Ishikawa T, Hirakawa K.
    Br J Cancer; 2004 Aug 31; 91(5):873-8. PubMed ID: 15280913
    [Abstract] [Full Text] [Related]

  • 4. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.
    Rodríguez CA, Cruz JJ, Martín T, Gómez A, Olaverri A, Hernández M.
    Cancer; 2002 Aug 01; 95(3):670-1; author reply 671. PubMed ID: 12209762
    [No Abstract] [Full Text] [Related]

  • 5. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L, Ceriani L, Giardina G, Bardelli D, Tanzi F, Garancini S.
    Clin Chem Lab Med; 2002 Mar 01; 40(3):298-303. PubMed ID: 12005221
    [Abstract] [Full Text] [Related]

  • 6. [Biomarkers in breast cancer].
    Kurebayashi J.
    Gan To Kagaku Ryoho; 2004 Jul 01; 31(7):1021-6. PubMed ID: 15272579
    [Abstract] [Full Text] [Related]

  • 7. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
    Kurebayashi J, Nomura T, Hirono M, Okubo S, Udagawa K, Shiiki S, Ikeda M, Nakashima K, Tanaka K, Sonoo H.
    Jpn J Clin Oncol; 2006 Mar 01; 36(3):150-3. PubMed ID: 16520359
    [Abstract] [Full Text] [Related]

  • 8. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
    Kaneko Y, Imoto S, Kasakura S.
    Rinsho Byori; 1995 Jul 01; 43(7):696-702. PubMed ID: 7674542
    [Abstract] [Full Text] [Related]

  • 9. A comparative study of four serological tumor markers for the detection of breast cancer.
    Clinton SR, Beason KL, Bryant S, Johnson JT, Jackson M, Wilson C, Holifield K, Vincent C, Hall M.
    Biomed Sci Instrum; 2003 Jul 01; 39():408-14. PubMed ID: 12724928
    [Abstract] [Full Text] [Related]

  • 10. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
    Bensouda Y, André F, Boulet T, Al-Ghuzlan A, Conforti R, Troalen F, Bourgier C, Errihani H, Spielmann M, Delaloge S.
    Bull Cancer; 2009 Oct 01; 96(10):923-8. PubMed ID: 19696005
    [Abstract] [Full Text] [Related]

  • 11. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
    Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Munoz M, Farrus B, Ballesta AM.
    Anticancer Res; 2003 Oct 01; 23(2A):1043-50. PubMed ID: 12820345
    [Abstract] [Full Text] [Related]

  • 12. Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors.
    Hernández L, Nuñez-Villarl MJ, Martínez-Arribas F, Pollán M, Schneider J.
    Anticancer Res; 2005 Oct 01; 25(1B):451-4. PubMed ID: 15816610
    [Abstract] [Full Text] [Related]

  • 13. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T, Schürenkämper P, Minguillon C, Lichtenegger W.
    Anticancer Res; 1997 Oct 01; 17(4B):2953-4. PubMed ID: 9329573
    [Abstract] [Full Text] [Related]

  • 14. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
    Nakamura T, Kimura T, Umehara Y, Suzuki K, Okamoto K, Okumura T, Morizumi S, Kawabata T.
    Surg Today; 2005 Oct 01; 35(1):19-21. PubMed ID: 15622458
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer.
    Ogawa Y, Ishikawa T, Ikeda K, Nakata B, Sawada T, Ogisawa K, Kato Y, Hirakawa K.
    Clin Cancer Res; 2000 Oct 01; 6(10):4069-72. PubMed ID: 11051258
    [Abstract] [Full Text] [Related]

  • 16. [Tumor markers in breast cancer].
    Kurebayashi J.
    Gan To Kagaku Ryoho; 2004 Nov 01; 31(12):2077-81. PubMed ID: 15570944
    [Abstract] [Full Text] [Related]

  • 17. [Comparison of the estrogen and progesterone receptor content of primary breast cancers without skeletal or visceral metastasis with tumor marker MCA, CEA and CA 15-3 serum concentration at the time of surgery].
    Seifert M, Wierrani F, Kubista E, Spona J.
    Gynakol Rundsch; 1991 Nov 01; 31 Suppl 2():397-8. PubMed ID: 1790992
    [No Abstract] [Full Text] [Related]

  • 18. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
    Zheng H, Luo RC.
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct 01; 25(10):1293-4, 1298. PubMed ID: 16234113
    [Abstract] [Full Text] [Related]

  • 19. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
    Hu XC, Day W, Jones B, Loo WT, Chow LW.
    Anticancer Res; 2002 Oct 01; 22(3):1865-8. PubMed ID: 12168883
    [Abstract] [Full Text] [Related]

  • 20. Biological markers in breast cancer prognosis and treatment.
    Kesisis G, Kontovinis LF, Gennatas K, Kortsaris AH.
    J BUON; 2010 Oct 01; 15(3):447-54. PubMed ID: 20941809
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.